TW202302637A - 抗cd30l抗體及其用途 - Google Patents

抗cd30l抗體及其用途 Download PDF

Info

Publication number
TW202302637A
TW202302637A TW111105667A TW111105667A TW202302637A TW 202302637 A TW202302637 A TW 202302637A TW 111105667 A TW111105667 A TW 111105667A TW 111105667 A TW111105667 A TW 111105667A TW 202302637 A TW202302637 A TW 202302637A
Authority
TW
Taiwan
Prior art keywords
amino acid
seq
acid sequence
cdr
sequence described
Prior art date
Application number
TW111105667A
Other languages
English (en)
Chinese (zh)
Inventor
傑西 法拉 菲克特奧
馬克 倫蕭
喬漢 法蘭森
奧立維爾 勞倫特
伯頓 巴奈特
Original Assignee
美商普羅米修斯生物科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商普羅米修斯生物科學股份有限公司 filed Critical 美商普羅米修斯生物科學股份有限公司
Publication of TW202302637A publication Critical patent/TW202302637A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111105667A 2021-02-17 2022-02-16 抗cd30l抗體及其用途 TW202302637A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163150373P 2021-02-17 2021-02-17
US63/150,373 2021-02-17

Publications (1)

Publication Number Publication Date
TW202302637A true TW202302637A (zh) 2023-01-16

Family

ID=82931610

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111105667A TW202302637A (zh) 2021-02-17 2022-02-16 抗cd30l抗體及其用途

Country Status (19)

Country Link
US (3) US20240254246A1 (enExample)
EP (1) EP4294840A4 (enExample)
JP (2) JP7559257B2 (enExample)
KR (1) KR20230157356A (enExample)
CN (2) CN117255802A (enExample)
AR (1) AR124895A1 (enExample)
AU (1) AU2022224561A1 (enExample)
BR (1) BR112023016445A2 (enExample)
CA (1) CA3208060A1 (enExample)
CL (1) CL2023002393A1 (enExample)
CO (1) CO2023011962A2 (enExample)
CR (1) CR20230445A (enExample)
EC (1) ECSP23070234A (enExample)
GE (3) GEAP202416351A (enExample)
IL (1) IL305146A (enExample)
MX (1) MX2023009621A (enExample)
PE (1) PE20231680A1 (enExample)
TW (1) TW202302637A (enExample)
WO (1) WO2022177963A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND THEIR USES
AU2022224561A1 (en) 2021-02-17 2023-09-28 Dr. Falk Pharma Gmbh Anti-cd30l antibodies and uses thereof
IL309562A (en) 2021-06-21 2024-02-01 Juvena Therapeutics Inc Regenerative polypeptides and their uses
AU2023315888A1 (en) * 2022-07-25 2025-02-06 Dr. Falk Pharma Gmbh Anti-cd30l antibodies, formulations therefor, and uses thereof
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物
WO2025059023A1 (en) * 2023-09-12 2025-03-20 Amgen Inc. Anti-cd30l antibodies and uses thereof
WO2025075049A1 (ja) * 2023-10-03 2025-04-10 国立大学法人京都大学 ヒトｃｄ１５３を標的とする抗体ならびにキメラ抗原受容体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DK0615451T3 (da) * 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005018571A2 (en) 2003-08-20 2005-03-03 University Of Miami Compositions and methods for treating inflammatory lung disease
WO2013059732A1 (en) * 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
AU2013251541B2 (en) * 2012-04-27 2018-01-25 Amgen Inc. Human CD30 ligand antigen binding proteins
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
WO2017127537A1 (en) 2016-01-19 2017-07-27 Thomas Blumenthal Down syndrome biomarkers and uses thereof
KR20250111409A (ko) * 2018-04-30 2025-07-22 세다르스-신나이 메디칼 센터 염증성 질환을 보유하는 환자의 선택 및 치료를 위한 방법 및 시스템
WO2020096046A1 (ja) 2018-11-09 2020-05-14 国立大学法人大阪大学 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
AU2022224561A1 (en) 2021-02-17 2023-09-28 Dr. Falk Pharma Gmbh Anti-cd30l antibodies and uses thereof

Also Published As

Publication number Publication date
CA3208060A1 (en) 2022-08-25
EP4294840A4 (en) 2025-06-11
US11866505B2 (en) 2024-01-09
AR124895A1 (es) 2023-05-17
WO2022177963A1 (en) 2022-08-25
CN118047872A (zh) 2024-05-17
CN117255802A (zh) 2023-12-19
IL305146A (en) 2023-10-01
GEAP202516710A (en) 2025-05-13
CO2023011962A2 (es) 2023-09-29
CL2023002393A1 (es) 2024-03-22
AU2022224561A9 (en) 2023-10-05
JP2025004013A (ja) 2025-01-14
US20230060624A1 (en) 2023-03-02
US20240254246A1 (en) 2024-08-01
US20240092923A1 (en) 2024-03-21
GEAP202416351A (en) 2024-02-12
AU2022224561A1 (en) 2023-09-28
KR20230157356A (ko) 2023-11-16
ECSP23070234A (es) 2023-10-31
JP2024509746A (ja) 2024-03-05
JP7559257B2 (ja) 2024-10-01
EP4294840A1 (en) 2023-12-27
MX2023009621A (es) 2023-10-31
BR112023016445A2 (pt) 2023-12-12
PE20231680A1 (es) 2023-10-19
GEP20257791B (en) 2025-09-10
CR20230445A (es) 2023-11-14

Similar Documents

Publication Publication Date Title
US11866505B2 (en) Anti-CD30L antibodies and uses thereof
JP7514363B2 (ja) Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
US10669344B2 (en) Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
JP2023080074A (ja) 抗ｔｒｅｍ－１抗体およびその使用
CN111819201A (zh) Pd1结合剂
CN111818972A (zh) 去免疫的抗erbb3抗体
CN111788229A (zh) Csf1r结合剂
US20250340660A1 (en) Anti-cd30l antibodies, formulations therefor, and uses thereof
IL297286A (en) Biosynthetic glycoprotein populations
US20250243286A1 (en) Antibodies Targeting ActRIIA and ActRIIB
JP2025535498A (ja) Ｃｄ２４に対する抗体およびその使用
WO2026002175A1 (zh) 靶向ilt7和cd89的髓细胞衔接子抗体及其用途
WO2024246356A1 (en) Silenced antibody-based anti-met constructs for the treatment of tumors and metastasis
JP2024544924A (ja) トランスサイレチン（ｔｔｒ）単量体結合抗体
CN121226557A (zh) 抗cMET抗体
CN121226555A (zh) 抗cMET抗体
EA046142B1 (ru) Антитела к trem-1 и их применения